How Regaining Full Rights to Rett Syndrome Gene Therapy Has Changed Taysha (TSHA)'s Investment Story [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
after the expiration of an option agreement with Astellas, following the submission of clinical trial data and receipt of Breakthrough Therapy designation from the FDA. This development leaves Taysha in a position to independently advance TSHA-102, a one-time treatment for Rett syndrome utilizing miRARE technology, with multiple regulatory designations highlighting its clinical and regulatory significance. We'll examine how Taysha's regained autonomy over its FDA-designated gene therapy could influence the company's investment outlook and growth prospects. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit Taysha Gene Therapies Investment Narrative Recap To own shares in Taysha Gene Therapies, investors must believe in the potential of TSHA-102 to achieve regulatory approval and transition to commercialization for Rett syndrome, overcoming the inherent risks of long clinical timelines and financial losses.
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Taysha Gene Therapies (NASDAQ:TSHA) was given a new $11.00 price target on by analysts at UBS Group AG.MarketBeat
- Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "buy" rating.MarketBeat
- Taysha Gene Therapies (NASDAQ:TSHA) was given a new $11.00 price target on by analysts at The Goldman Sachs Group, Inc..MarketBeat
- Taysha Gene Therapies (NASDAQ:TSHA) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
TSHA
Earnings
- 11/4/25 - In-Line
TSHA
Sec Filings
- 12/1/25 - Form 4
- 11/28/25 - Form 144
- 11/14/25 - Form SCHEDULE
- TSHA's page on the SEC website